JPH0575728B2 - - Google Patents
Info
- Publication number
- JPH0575728B2 JPH0575728B2 JP4155087A JP4155087A JPH0575728B2 JP H0575728 B2 JPH0575728 B2 JP H0575728B2 JP 4155087 A JP4155087 A JP 4155087A JP 4155087 A JP4155087 A JP 4155087A JP H0575728 B2 JPH0575728 B2 JP H0575728B2
- Authority
- JP
- Japan
- Prior art keywords
- platelet aggregation
- present
- pyrazine
- pyrazine derivative
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000003216 pyrazines Chemical class 0.000 claims description 19
- 229940127218 antiplatelet drug Drugs 0.000 claims description 7
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims description 7
- 101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 claims description 6
- 101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 claims description 6
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 230000000702 anti-platelet effect Effects 0.000 description 3
- 229940114079 arachidonic acid Drugs 0.000 description 3
- 235000021342 arachidonic acid Nutrition 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- YLBCZNNGPOPTGM-UHFFFAOYSA-N 2-chloro-3,5-diphenylpyrazine Chemical compound ClC1=NC=C(C=2C=CC=CC=2)N=C1C1=CC=CC=C1 YLBCZNNGPOPTGM-UHFFFAOYSA-N 0.000 description 2
- FYIHUZXWJJAIJW-UHFFFAOYSA-N 2-methyl-3,5-diphenylpyrazine Chemical compound CC1=NC=C(C=2C=CC=CC=2)N=C1C1=CC=CC=C1 FYIHUZXWJJAIJW-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010008132 Cerebral thrombosis Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000010446 mirabilite Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 210000004623 platelet-rich plasma Anatomy 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- RSIJVJUOQBWMIM-UHFFFAOYSA-L sodium sulfate decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-]S([O-])(=O)=O RSIJVJUOQBWMIM-UHFFFAOYSA-L 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
【発明の詳細な説明】
発明の背景
技術分野
本発明はピラジン誘導体を含有する血小板凝集
抑制剤に関する。
本発明のピラジン誘導体は強力な血小板凝集抑
制作用を有するので、血小板凝集に起因する疾患
即ち血栓症等の予防に有効である。
先行技術
抗血小板凝集作用を有する物質は種々知られて
いるが、作用が弱いものであり、より改善された
薬剤の出現が望まれている。また、心筋梗塞や脳
血栓といつた血栓症は、近年成人病の中で大きな
割合を占めるに至つており、これを有効に予防す
る抗血栓症剤の出現が望まれている。
従来種々のピラジン誘導体が知られており、ヘ
テロサイクルズ第22巻，第2317頁（1984年）には
３，５−ジフエニル−２−メチルピラジンが記載
されている。しかしながらこれらのピラジン誘導
体が抗血小板凝集抑制作用を有することはこれま
で知られていない。
発明の目的
本発明等はピラジン誘導体を合成し、それらの
薬理活性を鋭意研究した結果、特定のピラジン誘
導体が優れた血小板凝集抑制作用を有することを
見い出し、本発明を完成させた。
したがつて本発明は有効成分としてピラジン誘
導体を含有する血小板凝集抑制剤を提供すること
を目的とする。
かかる目的を達成するため本発明は下記の構成
を有する。
式（）DETAILED DESCRIPTION OF THE INVENTION BACKGROUND OF THE INVENTION Technical Field The present invention relates to platelet aggregation inhibitors containing pyrazine derivatives. Since the pyrazine derivatives of the present invention have a strong platelet aggregation inhibiting effect, they are effective in preventing diseases caused by platelet aggregation, such as thrombosis. PRIOR ART Although various substances having anti-platelet aggregation effects are known, their effects are weak, and there is a desire for the emergence of more improved drugs. In addition, thrombosis such as myocardial infarction and cerebral thrombosis has recently become a large proportion of adult diseases, and there is a desire for an antithrombotic agent to effectively prevent this. Various pyrazine derivatives have been known so far, and 3,5-diphenyl-2-methylpyrazine is described in Heterocycles, Vol. 22, p. 2317 (1984). However, it has not been known so far that these pyrazine derivatives have an anti-platelet aggregation inhibitory effect. Purpose of the Invention As a result of synthesizing pyrazine derivatives and intensively studying their pharmacological activities, the present inventors discovered that a specific pyrazine derivative has an excellent platelet aggregation inhibiting effect, and completed the present invention. Therefore, an object of the present invention is to provide a platelet aggregation inhibitor containing a pyrazine derivative as an active ingredient. In order to achieve this object, the present invention has the following configuration. formula()
【式】
を有するピラジン誘導体を含有する血小板凝集抑
制剤。
発明の具体的説明
本発明によれば前記式（）で示されるピラジ
ン誘導体を含有する血小板凝集抑制剤が提供され
る。
ピラジン誘導体（）は式（）A platelet aggregation inhibitor containing a pyrazine derivative having the formula: DETAILED DESCRIPTION OF THE INVENTION According to the present invention, a platelet aggregation inhibitor containing a pyrazine derivative represented by the above formula () is provided. Pyrazine derivative () has the formula ()
【式】
で示される２−クロロ−３，５−ジフエニルピラ
ジンを不活性有機溶媒（例えばジオキサン）中、
零価のパラジウム錯体を共存させてトリメチルア
ルミニウムと20〜120℃で加熱することにより製
造される。
本発明のピラジン誘導体（）は、血小板の凝
集を阻害する作用を有するので、血小板凝集抑制
剤として脳血栓等の予防に有効に使用される。投
与量は一般に成人１日量約30〜600mgであり、必
要により１〜３回に分けて投与するのがよい。投
与方法は投与に適した任意の形態をとることがで
き、特に経口投与が望ましいが、静注も可能であ
る。
本発明の化合物は単独または通常の方法で製剤
担体あるいは賦形剤と混合され、錠剤、散剤、カ
プセル剤、顆粒剤に製剤化される。担体あるいは
賦形剤の例として炭酸カルシウム、リン酸カルシ
ウム、でんぷん、しよ糖、乳糖、タルク、ステア
リン酸マグネシウム等があげられる。本発明の化
合物は、上記の固形剤の他に油性懸濁剤、シロツ
プのような液剤とすることもできる。
本発明の化合物をサイクロデキストリンで包接
し安定化することもできる。
次に製造例および薬理試験例を示して本発明を
さらに具体的に説明する。
製造例
アルゴン気流下２−クロロ−３，５−ジフエニ
ルピラジン（1.596ｇ）とテトラキス（トリフエ
ニルホスフイン）パラジウム（348mg）に無水ジ
オキサン（20ml）を加え、ついで15％トリメチル
アルミニウムのｎ−ヘキサン溶液（２ml）を室温
下、少量ずつ加えた後、２時間加熱還流する。反
応後、水を加え塩化メチレンで抽出し、該塩化メ
チレン層を芒硝で乾燥し、次いで溶媒を留去後、
シリカゲルカラムクロマトグラフイーに付す。ｎ
−ヘキサン−塩化メチレン（10：１）溶出区分を
とり、溶媒を留去し、残留物をｎ−ヘキサンより
再結晶することにより、３，５−ジフエニル−２
メチルピラジン（1.40ｇ）を得た。このものの物
理化学的データは下記式（）の構造を支持す
る。
融点 90.5〜91.5℃
元素分析値 C17H14N2に対する
計算値：Ｃ，82.90％；Ｈ，5.73％
Ｎ，11.37％
実測値：Ｃ，83.04％；Ｈ，5.76％
Ｎ，11.38％
MASS（ｍ／ｅ）：246（分子イオンピーク）
1H−NMR（CDCl3）δ（ppm）：2.60（3H，ｓ），
7.27〜7.70（8H，ｍ），7.87〜8.07（2H，
ｍ），8.77（1H，ｅ）2-chloro-3,5-diphenylpyrazine represented by the formula in an inert organic solvent (e.g. dioxane),
It is produced by heating trimethylaluminum at 20 to 120°C in the coexistence of a zero-valent palladium complex. Since the pyrazine derivative () of the present invention has an action of inhibiting platelet aggregation, it can be effectively used as a platelet aggregation inhibitor to prevent cerebral thrombosis and the like. The dosage is generally about 30 to 600 mg per day for adults, and should be divided into 1 to 3 doses if necessary. The method of administration can take any form suitable for administration, with oral administration being particularly preferred, although intravenous injection is also possible. The compound of the present invention may be formulated into tablets, powders, capsules, or granules either alone or mixed with pharmaceutical carriers or excipients in a conventional manner. Examples of carriers or excipients include calcium carbonate, calcium phosphate, starch, sucrose, lactose, talc, magnesium stearate, and the like. In addition to the solid formulations mentioned above, the compounds of the present invention can also be formulated into liquid formulations such as oily suspensions and syrups. The compound of the present invention can also be stabilized by inclusion with cyclodextrin. Next, the present invention will be explained in more detail by showing production examples and pharmacological test examples. Production example Anhydrous dioxane (20 ml) was added to 2-chloro-3,5-diphenylpyrazine (1.596 g) and tetrakis(triphenylphosphine) palladium (348 mg) under an argon atmosphere, and then 15% trimethylaluminum in n-hexane The solution (2 ml) was added little by little at room temperature, and the mixture was heated under reflux for 2 hours. After the reaction, water was added and extracted with methylene chloride, the methylene chloride layer was dried with Glauber's salt, and then the solvent was distilled off.
Subject to silica gel column chromatography. n
The 3,5-diphenyl-2
Methyl pyrazine (1.40 g) was obtained. The physicochemical data of this product support the structure of the following formula (). Melting point 90.5-91.5℃ Elemental analysis value Calculated value for C 17 H 14 N 2 : C, 82.90%; H, 5.73% N, 11.37% Actual value: C, 83.04%; H, 5.76% N, 11.38% MASS (m /e): 246 (molecular ion peak) 1 H-NMR (CDCl 3 ) δ (ppm): 2.60 (3H, s),
7.27~7.70 (8H, m), 7.87~8.07 (2H,
m), 8.77 (1H, e)
【式】
薬理試験例 １
血小板凝集抑制作用
3.8％クエン酸ナトリウム溶液（１容）を入れ
注射器を用いてウサギ頚動脈より９容の血液を採
取する。該血液を遠心分離し、血小板に富む血漿
（PRP：７×105個／μを得る。該PRP268μ
をキユベツトに入れ、37℃恒温槽で２分間加温
し、試験するピラジン誘導体のエタノール溶液
2μを加え３分間インキユベツトした後、血小
板の凝集惹灯起剤であるアラキドン酸溶液あるい
はコラーゲン溶液を加え血小板凝集をボーン
（Born）比濁法〔たとえばジヤーナル・オブ・フ
イジオロジー（Ｊ，Physiol，第168巻，第178頁，
1968年発行）に記載されている〕で測定した。ア
ラキドン酸（50マイクロモル）またはコラーゲン
（10μｇ／ml）によつて惹起される血小板凝集に
対する50％抑制温度を表１に示す。アセチルサリ
チル酸を比較例として用いた。
表１に示す如く本発明のピラジン誘導体は顕著
な抗血小板凝集活性を示した。
尚、表中50％阻害濃度とは本発明に係るピラジ
ン誘導体を導入しない場合の血小板の凝集能を
100％とした場合、該ピラジン誘導体の導入によ
り前記血小板の凝集能を50％まで抑制する為に要
したピラジン誘導体溶液濃度を意味する。[Formula] Pharmacological test example 1 Platelet aggregation inhibitory effect Add 3.8% sodium citrate solution (1 volume) and collect 9 volumes of blood from the rabbit carotid artery using a syringe. The blood is centrifuged to obtain platelet-rich plasma (PRP: 7×10 5 cells/μ. The PRP is 268μ
was placed in a cuvette and heated for 2 minutes in a constant temperature bath at 37°C to prepare an ethanol solution of the pyrazine derivative to be tested.
After adding 2μ and incubating for 3 minutes, arachidonic acid solution or collagen solution, which is a platelet aggregation inducing agent, was added and platelet aggregation was measured using the Born nephelometric method [for example, Journal of Physiology (J, Physiol, No. 168). Volume, page 178,
(published in 1968)]. The 50% inhibition temperatures for platelet aggregation induced by arachidonic acid (50 micromoles) or collagen (10 μg/ml) are shown in Table 1. Acetylsalicylic acid was used as a comparative example. As shown in Table 1, the pyrazine derivatives of the present invention exhibited significant antiplatelet aggregation activity. In addition, the 50% inhibitory concentration in the table refers to the aggregation ability of platelets when the pyrazine derivative according to the present invention is not introduced.
In the case of 100%, it means the concentration of the pyrazine derivative solution required to suppress the aggregation ability of the platelets to 50% by introducing the pyrazine derivative.
【表】
急性毒性
ICR系雄性マウス（５週令）を用いて、経口投
与による急性毒性試験を行つた。本発明のピラジ
ン誘導体のLD50値は300mg／Kg以上であり、高い
安全性が確認された。
発明の効果
本発明によればピラジン誘導体を含有する血小
板凝集抑制剤が提供される。
本発明の上記化合物はアラキドン酸あるいはコ
ラーゲンによつて誘起される血小板凝集作用を顕
著に抑制するので、血小板凝集に起因する疾患、
特に心筋梗塞、脳出血の虚血性発作、脳梗塞等血
小板凝集の関与する血栓症の予防剤として使用す
ることができる。[Table] Acute toxicity An acute toxicity test was conducted by oral administration using ICR male mice (5 weeks old). The LD 50 value of the pyrazine derivative of the present invention was 300 mg/Kg or more, and high safety was confirmed. Effects of the Invention According to the present invention, a platelet aggregation inhibitor containing a pyrazine derivative is provided. The above-mentioned compounds of the present invention significantly inhibit platelet aggregation induced by arachidonic acid or collagen, thereby preventing diseases caused by platelet aggregation.
In particular, it can be used as a prophylactic agent for thrombosis involving platelet aggregation, such as myocardial infarction, ischemic attack due to cerebral hemorrhage, and cerebral infarction.
Claims (1)
抑制剤。[Claims] 1. A platelet aggregation inhibitor containing a pyrazine derivative represented by the formula () [Formula].
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP4155087A JPS63208520A (en) | 1987-02-26 | 1987-02-26 | Blood platelet agglutination inhibitor containing pyrazine derivative |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP4155087A JPS63208520A (en) | 1987-02-26 | 1987-02-26 | Blood platelet agglutination inhibitor containing pyrazine derivative |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS63208520A JPS63208520A (en) | 1988-08-30 |
| JPH0575728B2 true JPH0575728B2 (en) | 1993-10-21 |
Family
ID=12611534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP4155087A Granted JPS63208520A (en) | 1987-02-26 | 1987-02-26 | Blood platelet agglutination inhibitor containing pyrazine derivative |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS63208520A (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3354650T (en) | 2008-12-19 | 2022-06-20 | Vertex Pharma | Compounds useful as inhibitors of atr kinase |
| JP2013526540A (en) * | 2010-05-12 | 2013-06-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Compounds useful as ATR kinase inhibitors |
| MX2012013081A (en) | 2010-05-12 | 2013-05-09 | Vertex Pharma | Compounds useful as inhibitors of atr kinase. |
| CA2850566C (en) | 2011-09-30 | 2022-05-03 | Vertex Pharmaceuticals Incorporated | Process for making 4-[chloro-n-hydroxycarbonimidoyl]phenyl derivative |
| IN2014CN02501A (en) | 2011-09-30 | 2015-06-26 | Vertex Pharma | |
| JP2015515478A (en) | 2012-04-05 | 2015-05-28 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Compounds useful as inhibitors of ATR kinases and combinations thereof |
| EP2904406B1 (en) | 2012-10-04 | 2018-03-21 | Vertex Pharmaceuticals Incorporated | Method for measuring atr inhibition mediated increases in dna damage |
| CA3000684A1 (en) | 2015-09-30 | 2017-04-06 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of dna damaging agents and atr inhibitors |
-
1987
- 1987-02-26 JP JP4155087A patent/JPS63208520A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS63208520A (en) | 1988-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4847265A (en) | Dextro-rotatory enantiomer of methyl alpha-5 (4,5,6,7-tetrahydro (3,2-c) thieno pyridyl) (2-chlorophenyl)-acetate and the pharmaceutical compositions containing it | |
| EP0017195B1 (en) | Derivatives of 2,5-disubstituted-cyclohexane-1,3-diones, process for preparation thereof and pharmaceutical composition containing them | |
| US4619938A (en) | Fatty acid derivatives of aminoalkyl nicotinic acid esters and platelet aggregation inhibitors | |
| JPH0575728B2 (en) | ||
| JPS61172861A (en) | Isoquinolinethromboxane synthetase inhibitor | |
| JPS62270564A (en) | Pyrazine derivative and inhibitor of blood platelet aggregation containing same | |
| WO1996015117A1 (en) | Optically active compound | |
| US4794115A (en) | Method of treating hyperlipemia | |
| JPH0514708B2 (en) | ||
| JPH0530832B2 (en) | ||
| JPS63225354A (en) | Azetidinone derivative | |
| JPS637558B2 (en) | ||
| JPH0224270B2 (en) | ||
| JPH0515706B2 (en) | ||
| JPH0248545B2 (en) | 33PIRIJINKARUBONSANN11OKISHIDOJUDOTAIOYOBIKOREOGANJUSURUKETSUSHOBANGYOSHUYOKUSEIZAI | |
| JPS62174060A (en) | 5-fluorouracil derivative and drug preparation containing same | |
| JPH0153849B2 (en) | ||
| JPH0113703B2 (en) | ||
| JPH0368844B2 (en) | ||
| JPH0536435B2 (en) | ||
| JPS6323188B2 (en) | ||
| JPS6144853A (en) | Gamma-linoleic acid derivative and thrombocyte coagulation suppressing agent containing same | |
| JPS632547B2 (en) | ||
| JP2894617B2 (en) | 2-phenylindole derivatives | |
| JPH0466474B2 (en) |